Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PHVS
SELLPharvaris N.V. · Healthcare · Switzerland · $2.4B · Avg Vol: $16M/d
COMPANY DESCRIPTION
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative oral bradykinin-B2-receptor antagonists for rare diseases, specifically hereditary angioedema (HAE). The company's competitive edge is derived from its oral drug candidates, which aim to offer convenience and improved patient experience compared to existing injectable therapies. Its success hinges on clinical trial outcomes and regulatory approvals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 44.6M | — |
| EPS | -1.25 | -2.99 | -2.82 | -3.38 | — | -3.10 | -3.01 | -2.78 | — |
| Shares | 69.9M | 52.3M | 54.4M | 65.2M | -6.7% | 69.9M | — | — | — |
| Debt | 0.5M | 0.3M | 1.0M | 0.9M | 21.2% | 0.8M | — | — | — |
| Equity | 169.8M | 436.9M | 304.6M | 308.6M | 22.0% | — | — | — | — |
| Op CF | -76.4M | -105.8M | -136.7M | -155.9M | — | -167.8M | — | — | — |
| Inv CF | -0.1M | -0.1M | -0.6M | -0.2M | — | — | — | — | — |
| Fin CF | 9.8M | 370.1M | 3.0M | 182.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHVS | Pharvaris N.V.(you) | $2.4B | 26 | SELL |
| IDIA.SW | Idorsia Ltd | $2.2B | 33 | SELL |
| MLTX | MoonLake Immunotherapeutics | $1.6B | 18 | STRONG SELL |
| CRSP | CRISPR Therapeutics AG | $4.6B | 14 | STRONG SELL |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 24 | SELL |
| OCS | Oculis Holding AG | $672M | 7 | STRONG SELL |
| 0QNA.L | Basilea Pharmaceutica AG | $733M | 49 | HOLD |
| BANB.SW | Bachem Holding AG | $6.7B | 52 | HOLD |
| ACIU | AC Immune SA | $299M | 10 | STRONG SELL |
| MOLN.SW | Molecular Partners AG | $147M | 22 | SELL |
Peer medians: ROE 12.1% · P/E 26.3x · Gross margin 55.5%